Stock Taper
SCREENER COMPARE ANY 2 STOCKS
GNPX
GENPREX, INC.
NASDAQ
$3.67
▲ UP 1.66% (0.06)

KEY STATISTICS

Market Cap$1.85 M
52w High$1210.00
52w Low$3.57
Dividend Yield—
Frequency—
P/E-0.24
Volume53.94K
Shares Out.504.94K

COMPANY

LEADERSHIP

Ryan Confer
CHIEF EXECUTIVE
Ryan Confer

COMPENSATION 2026

Salary$480,000
Stock Awards$90,450
Incentive Plan Pay$0
All Other Comp.$62,421
Total$728,871

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 29, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
13

UPCOMING EARNINGS

DateDec 2, 2026
DayWednesday
Rev. Est.—
DEC
2
WED

SPLIT RECORD

DATETYPERATIO
2026-07-16Reverse1:22
2025-10-21Reverse1:50
2024-02-02Reverse1:40

PRICE

$3.67 ▲ UP 1.66% (+$0.06)
OVERLAYS
$3.64$3.68$3.729:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM3.67

About Genprex, Inc.

https://www.genprex.com ↗

Genprex, Inc. is a clinical-stage gene therapy company in Austin, Texas, developing treatments for cancer (REQORSA for lung cancers) and diabetes (GPX-002).

INDUSTRY

Biotechnology

A PRODUCT GENPREX, INC. IS KNOWN FOR

REQORSA® (quaratusugene ozeplasmid)
REQORSA® (quaratusugene ozeplasmid)

REQORSA® is Genprex's lead gene therapy candidate, in clinical trials for NSCLC and SCLC, delivering tumor suppressor genes via a proprietary non-viral system, and has FDA Fast Track designation for NSCLC.

COMPETITORS

COMPETITOR
AMGN COMPARE
CADL COMPARE
JAZZ COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
VXF
0.00% · 1.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
37
TOP 12 OF 37 · RANKED BY POSITION SIZE
Vanguard Group Inc
433.4K sh · $73.24K
Susquehanna International Group, Llp
340.1K sh · $57.6K
Jane Street Group, LLC
205.2K sh · $34.76K
Geode Capital Management, LLC
164.0K sh · $27.79K
Ubs Group AG
162.2K sh · $27.41K
Mayflower Financial Advisors, LLC
20.0K sh · $36.2K
Manchester Financial Inc
20.0K sh · $36.2K
Tcg Advisory Services, LLC
17.0K sh · $2.88K
Blackrock Inc.
11.4K sh · $21.48K
Blackrock, Inc.
9.4K sh · $1.59K
Advisor Group Holdings, Inc.
8.6K sh · $1.39K
Citigroup Inc
6.1K sh · $1.03K

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book5
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Tim Moore
Tim Moore
Purchase
2026-02-05

INSIDER TRADES

★
DIRECTOR
LONGNECKER BRENT M
Sale · 8 shares
2026-04-14
★
DIRECTOR
LONGNECKER BRENT M
Sale · 10 shares
2026-04-14
★
OFFICER: CHIEF MEDICAL OFFICER
Berger Mark Stanley
Sale · 7.2K shares
2026-02-27
★
DIRECTOR, OFFICER: PRESIDENT, CEO AND CFO
Confer Ryan M.
Sale · 9.3K shares
2026-02-27

SECTORS PEERS

PEERPRICE
CMMB$2.71COMPARE
BIVI$2.16COMPARE
CNSP$5.52COMPARE
LIMN$4.23COMPARE
INM$1.38COMPARE
BDRX$0.87COMPARE
CERO$0.01COMPARE
GRI$1.92COMPARE